WO2020149026A9 - Ｐｄ－１シグナル阻害剤含有薬剤による治療有効性の予測及び／又は判定マーカー - Google Patents

Ｐｄ－１シグナル阻害剤含有薬剤による治療有効性の予測及び／又は判定マーカー Download PDF

Info

Publication number
WO2020149026A9
WO2020149026A9 PCT/JP2019/046582 JP2019046582W WO2020149026A9 WO 2020149026 A9 WO2020149026 A9 WO 2020149026A9 JP 2019046582 W JP2019046582 W JP 2019046582W WO 2020149026 A9 WO2020149026 A9 WO 2020149026A9
Authority
WO
WIPO (PCT)
Prior art keywords
cells
effectiveness
treatment
drug containing
signal inhibitor
Prior art date
Application number
PCT/JP2019/046582
Other languages
English (en)
French (fr)
Other versions
WO2020149026A8 (ja
WO2020149026A1 (ja
Inventor
本庶　佑
健司 茶本
松田　文彦
Original Assignee
国立大学法人京都大学
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 国立大学法人京都大学 filed Critical 国立大学法人京都大学
Priority to US17/420,218 priority Critical patent/US20220082554A1/en
Priority to JP2020566134A priority patent/JPWO2020149026A1/ja
Priority to EP19909811.2A priority patent/EP3906942A4/en
Priority to CN201980085471.8A priority patent/CN113226370A/zh
Publication of WO2020149026A1 publication Critical patent/WO2020149026A1/ja
Publication of WO2020149026A8 publication Critical patent/WO2020149026A8/ja
Publication of WO2020149026A9 publication Critical patent/WO2020149026A9/ja
Priority to JP2024012632A priority patent/JP2024045362A/ja

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5091—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing the pathological state of an organism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57423—Specifically defined cancers of lung

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Pathology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • General Physics & Mathematics (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Toxicology (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)

Abstract

本発明は、下記の(i)及び／又は(ii)を指標として、PD-1シグナル阻害剤を含む薬剤による治療の有効性を予測及び/又は判定することを含む、検査法を提供する。 (i) 血清及び／又は血漿におけるマイクロバイオーム、エネルギー代謝および酸化還元に関連するメタボライト、(ii) 末梢血における、末梢血単核球（PBMC）中のCD4+ T細胞の頻度、CD8+T細胞集団の頻度、CD4+T細胞のミトコンドリア活性酸素発現量に対するCD8+T細胞のミトコンドリア活性酸素発現量の比、並びにCD8+T細胞のPGC-1α及びPGC-1βの発現からなる群より選択される少なくとも一つの細胞マーカー
PCT/JP2019/046582 2019-01-04 2019-11-28 Ｐｄ－１シグナル阻害剤含有薬剤による治療有効性の予測及び／又は判定マーカー WO2020149026A1 (ja)

Priority Applications (5)

Application Number Priority Date Filing Date Title
US17/420,218 US20220082554A1 (en) 2019-01-04 2019-11-28 Prediction and/or Determination Marker for Effectiveness of Treatment with Drug Containing PD-1 Signal Inhibitor
JP2020566134A JPWO2020149026A1 (ja) 2019-01-04 2019-11-28 Ｐｄ−１シグナル阻害剤含有薬剤による治療有効性の予測及び／又は判定マーカー
EP19909811.2A EP3906942A4 (en) 2019-01-04 2019-11-28 MARKER FOR PREDICTING AND/OR DETERMINING THE EFFECTIVENESS OF TREATMENT WITH A MEDICINE CONTAINING A PD-1 SIGNAL INHIBITOR
CN201980085471.8A CN113226370A (zh) 2019-01-04 2019-11-28 利用含有pd-1信号抑制剂的药剂的治疗有效性的预测和/或判定标记
JP2024012632A JP2024045362A (ja) 2019-01-04 2024-01-31 Ｐｄ－１シグナル阻害剤含有薬剤による治療有効性の予測及び／又は判定マーカー

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2019000181 2019-01-04
JP2019-000181 2019-01-04

Publications (3)

Publication Number Publication Date
WO2020149026A1 WO2020149026A1 (ja) 2020-07-23
WO2020149026A8 WO2020149026A8 (ja) 2020-09-17
WO2020149026A9 true WO2020149026A9 (ja) 2020-10-29

Family

ID=71614211

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2019/046582 WO2020149026A1 (ja) 2019-01-04 2019-11-28 Ｐｄ－１シグナル阻害剤含有薬剤による治療有効性の予測及び／又は判定マーカー

Country Status (6)

Country Link
US (1) US20220082554A1 (ja)
EP (1) EP3906942A4 (ja)
JP (2) JPWO2020149026A1 (ja)
CN (1) CN113226370A (ja)
TW (1) TW202043773A (ja)
WO (1) WO2020149026A1 (ja)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20240085417A1 (en) * 2021-01-20 2024-03-14 Memorial Sloan Kettering Cancer Center Peripheral blood phenotype linked to outcomes after immunotherapy treatment
WO2022212286A1 (en) * 2021-03-28 2022-10-06 Peter Peizhi Luo Methods for treating cancer using anti-ctla4 antibodies
WO2022243905A1 (en) * 2021-05-18 2022-11-24 Imel Biotherapeutics, Inc. Methods and compositions for reducing immune cell exhaustion using mitochondria replacement
WO2023127543A1 (ja) * 2021-12-28 2023-07-06 国立大学法人大阪大学 免疫チェックポイント阻害剤による重篤な有害事象の発生の予測を補助する方法、予測補助装置
CN115192716A (zh) * 2022-08-09 2022-10-18 中国人民解放军空军特色医学中心 用于预测、预防或治疗术后谵妄症的方法及系统

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109844536B (zh) * 2016-09-26 2023-04-14 豪夫迈·罗氏有限公司 预测对pd-1轴抑制剂的响应
CN116196425A (zh) * 2016-09-27 2023-06-02 得克萨斯系统大学评议会 通过调节微生物组来增强免疫检查点阻断疗法的方法
CN109996886A (zh) * 2016-11-02 2019-07-09 国立大学法人京都大学 Pd-1信号抑制剂疾病治疗中有效性判定标记
WO2018115519A1 (en) * 2016-12-22 2018-06-28 Institut Gustave Roussy Microbiota composition, as a marker of responsiveness to anti-pd1/pd-l1/pd-l2 antibodies and use of microbial modulators for improving the efficacy of an anti-pd1/pd-l1/pd-l2 ab-based treatment
JP2018134038A (ja) * 2017-02-22 2018-08-30 小野薬品工業株式会社 Ｐｄ−１経路阻害薬による癌治療に有効性を示す患者選択のためのバイオマーカー
JP2019000181A (ja) 2017-06-12 2019-01-10 株式会社オリンピア 遊技機

Also Published As

Publication number Publication date
EP3906942A1 (en) 2021-11-10
WO2020149026A8 (ja) 2020-09-17
US20220082554A1 (en) 2022-03-17
EP3906942A4 (en) 2023-02-22
CN113226370A (zh) 2021-08-06
JP2024045362A (ja) 2024-04-02
TW202043773A (zh) 2020-12-01
WO2020149026A1 (ja) 2020-07-23
JPWO2020149026A1 (ja) 2021-11-18

Similar Documents

Publication Publication Date Title
WO2020149026A9 (ja) Ｐｄ－１シグナル阻害剤含有薬剤による治療有効性の予測及び／又は判定マーカー
Lombardi et al. Early phases of COVID-19 are characterized by a reduction in lymphocyte populations and the presence of atypical monocytes
Piekna-Przybylska et al. Deficiency in DNA damage response, a new characteristic of cells infected with latent HIV-1
Langford et al. Predictors of disease progression in HIV infection: a review
Wieland et al. Biomarkers as a tool for management of immunosuppression in transplant patients
Pang et al. Activated Galectin‐9/Tim3 promotes Treg and suppresses Th1 effector function in chronic lymphocytic leukemia
McNamara et al. CD133+ hematopoietic progenitor cells harbor HIV genomes in a subset of optimally treated people with long-term viral suppression
Sellebjerg et al. FOXP3, CBLB and ITCH gene expression and cytotoxic T lymphocyte antigen 4 expression on CD4+ CD25high T cells in multiple sclerosis
Oylumlu et al. Relationship between platelet-to-lymphocyte ratio and coronary slow flow
Zhu et al. SOAT1 promotes gastric cancer lymph node metastasis through lipid synthesis
Pastor et al. Dynamics of CD4 and CD8 T-cell subsets and inflammatory biomarkers during early and chronic HIV infection in Mozambican adults
Araujo Furlan et al. Limited Foxp3+ regulatory T cells response during acute Trypanosoma cruzi infection is required to allow the emergence of robust parasite-specific CD8+ T cell immunity
Hoerning et al. Pharmacodynamic monitoring of mammalian target of rapamycin inhibition by phosphoflow cytometric determination of p70S6 kinase activity
Díaz et al. The clinical recovery of tuberculosis patients undergoing specific treatment is associated with changes in the immune and neuroendocrine responses
Marcucci et al. Residual platelet reactivity is an independent predictor of myocardial injury in acute myocardial infarction patients on antiaggregant therapy
Lamprecht et al. Elevated monocytic IL-12 and TNF-α production in Wegener's granulomatosis is normalized by cyclophosphamide and corticosteroid therapy
Liu et al. Activation of peripheral blood CD3+ T-lymphocytes in patients with atrial fibrillation
Walter et al. The relationship between peripheral immune response and disease severity in SARS‐CoV‐2‐infected subjects: A cross‐sectional study
Alsadhan et al. CD49d expression identifies a biologically distinct subtype of chronic lymphocytic leukemia with inferior progression-free survival on BTK inhibitor therapy
Kidir et al. Telomerase activity in patients with stage 2–5D chronic kidney disease
Gao et al. Clinical significance and correlation of microRNA-21 expression and the neutrophil-lymphocyte ratio in patients with acute myocardial infarction
Pannus et al. In-vitro viral suppressive capacity correlates with immune checkpoint marker expression on peripheral CD8+ T cells in treated HIV-positive patients
Mushtaque et al. Role of cardio-specific micro-ribonucleic acids and correlation with cardiac biomarkers in acute coronary syndrome: a comprehensive systematic review
Visalli et al. Intracellular accumulation of cell cycle regulatory proteins and nucleolin re-localization are associated with pre-lethal ultrastructural lesions in circulating T lymphocytes: The HIV-induced cell cycle dysregulation revisited
Welzl et al. How immunosuppressive therapy affects T cells from kidney transplanted patients of different age: the role of latent cytomegalovirus infection

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 19909811

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 2020566134

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2019909811

Country of ref document: EP

Effective date: 20210804